ADC Therapeutics announced new data on ZYNLONTA, an antibody drug conjugate, showing high response rates and durable effects in several lymphoma types including relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and marginal zone lymphoma (MZL). Key studies like LOTIS-7 and a Phase 2 trial in MZL reported overall response rates above 88% and complete response rates over 74%, with manageable safety profiles. The Phase 3 LOTIS-5 study showed ZYNLONTA plus rituximab significantly improved progression-free survival compared to standard treatment. These results support ongoing development and potential expanded use of ZYNLONTA in B-cell malignancies, with further Phase 3 trials planned.
ADC Therapeutics' ZYNLONTA clinical program is the subject, with Pluang's Health sector data providing context. Among 150 US health stocks tradable on Pluang, 127 rose and 19 fell as of Nov 04, 2026 20:41 WIB. Notably, Canopy Growth Corp (CGC) gained 5.70% at USD 0.75 with a typical hold time of 40 days and 100% buy orders, while Novo Nordisk (NVO) rose 5.50% to USD 42.40 with a longer hold time of 118 days and 90% buy orders. Amgen (AMGN) also increased 5.47% to USD 486.50, held typically for 73 days with 68% buy orders.
The National Advertising Division (NAD) recommended that Good Life Meds discontinue claims about health benefits and personalization for its compounded Tirzepatide+ weight loss products after a challenge by Eli Lilly. NAD found that Good Life lacked ...
Moleculin Biotech announced that interim results from its Phase 2/3 trial of Annamycin for relapsed or refractory acute myeloid leukemia (AML) will be presented at the 2026 ASH Annual Meeting. The trial showed remission rates of 43% and 36% in two An...
The Australia and New Zealand (ANZ) dental implants market, valued at $266 million in 2025, is projected to grow at a 5% CAGR to $393 million by 2033. Growth is driven by increasing demand for oral rehabilitation and prosthetic dentistry, especially ...
Asgard Therapeutics published a study in Immunity demonstrating its technology can reprogram tumor cells into dendritic cells, inducing cancer-fighting tertiary lymphoid structures (imgTLSs) across seven tumor types. This tumor-agnostic approach led ...
Cap, an onchain credit marketplace, is expanding into film and media financing by providing funding for the upcoming film Wake. This deal uses advances against anticipated film production tax credits, showing how Cap's underwriting model supports spe...
